4D Molecular Therapeutics Reports Q2 2026 Financial Results

What Happened

• On August 13, 2026, 4D Molecular Therapeutics, Inc. (4DMT) announced and furnished its financial results for the three months ended June 30, 2026. The company provided a press release titled “4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones” as Exhibit 99.1 to the Form 8-K.

Key Details

• Reporting period: three months ended June 30, 2026.
• Filing date: August 13, 2026 (Form 8-K, Item 2.02).
• Exhibit furnished: 99.1 — press release with Q2 2026 results, operational highlights and expected upcoming milestones; Exhibit 104 (Inline XBRL cover page).
• Report signed on behalf of the company by Kristian Humer, Chief Financial Officer.

Why It Matters

• The 8-K makes 4DMT’s latest quarterly financial results and operational update public; investors should read the furnished press release for specifics on revenue, expenses, cash position, clinical or program milestones and any forward-looking commentary. This filing is a routine way the company communicates quarterly performance and near-term expectations to the market.